This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. ABSTRACT Oxadiazole compounds are of great interest because they have a range of biological activities ranging from antioxidants to anticancer agents. Against this background, we wanted to demonstrate the antioxidant, enzyme inhibitory, and anticancer effects of 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole (Hppo).
Today we launch Issue 05 of Asimov Press. Read our full Editors’ Note and preview upcoming articles on our website. Thanks for reading! Edwin Cohn, a temperamental and entrepreneurial protein chemist working at Harvard University in the early 1900s, is perhaps one of the most underrated translational scientists of all time. In 1940, with the likelihood of America’s involvement in World War II steadily rising, the U.S. military approached Cohn about developing medical products from bl
Dex decreased SOX9 expression and then reduced the transcriptional activation of DMT1, ameliorating ferroptosis to improve cerebral ischemia/reperfusion injury. ABSTRACT Cerebral ischemia/reperfusion injury (IRI) is pathologically associated with ferroptosis. Dexmedetomidine (Dex) exerts neuroprotective activity after cerebral IRI. Our work focused on probing the pharmacologic effect of Dex on ferroptosis during cerebral IRI and the mechanisms involved.
By Deborah L. Livornese As promised in the Fall Unified Regulatory Agenda, FDA issued the final rule to establish the pathway to obtain marketing approval of a nonprescription drug product with an additional condition for nonprescription use (ACNU) on December 26, 2024, before the end of the calendar year. 89 Fed. Reg. 105288 (Dec. 26, 2024). We described the 2022 proposed rule and the ten-plus year history leading up to its issuance in our blog post here.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Big news, Trailblazers! If youve ever worked with Lightning Web Components (LWC) , youve likely used the good old if:true and if:false directives for conditional rendering. These directives have served us well, but Salesforce has introduced a much-needed upgrade! Say hello to the modern conditional rendering directives : lwc:if, lwc:elseif, and lwc:else.
Imagine this: youre on a treasure hunt. The treasure is hidden in a locked vault, and to open it, you need the right key. In Salesforce, when you need to access external systems, the key is what we call External Credentials and Named Credentials. But what exactly are they? Lets dive into this journey together and unravel their secrets in a simple and beginner-friendly way.
Imagine this: youre on a treasure hunt. The treasure is hidden in a locked vault, and to open it, you need the right key. In Salesforce, when you need to access external systems, the key is what we call External Credentials and Named Credentials. But what exactly are they? Lets dive into this journey together and unravel their secrets in a simple and beginner-friendly way.
52
52
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
100 
Let's personalize your content